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Local tumor immune response and host immunity have been suggested as important prognosticators 
respectively in colorectal cancer. However, the utility of combination of these parameters remains 
inconclusive. The aim of this study was to investigate the combinational impact of local and host 
tumor immune response, as determined by tumor-infiltrating lymphocytes (TILs) and neutrophil-to-
lymphocyte ratio (NLR), in patients with stage III colon cancer. Patients with stage III colon cancer 
homogeneously treated with surgery followed by FOLFOX chemotherapy between Jan 2007 and Aug 
2013 were included retrospectively. Hematoxylin and eosin (H&E) stained tumor sections of local 
inflammatory infiltrate (TILs) were classified as 0–3 by the Klintrup-Mäkinen grading method. NLR was 
measured within 1 month of surgery. The association of NLR and TILs with survival, alone or combined, 
were measured using multivariate Cox proportional hazard regression analysis. Among 137 patients, 
75 (54.7%) were identified as the high TIL group (TILs 2 and 3) and 97 (70.8%) as the low NLR group 
(NLR < 3). Of the patients with high TILs, 51 (68%) had a low NLR. In univariate analysis, operation 
time, complications, lymph node ratio (LNR), stage, TILs, and high TILs with low NLR were significantly 
associated with overall survival(OS). Multivariate Cox regression identified operation time, stage, 
and TILs as independent risk factors for OS. When high TILs with low NLR vs. others was entered into 
multivariate analysis, this also proved to be a significant predictor of OS (HR 4.1, 95% CI 1.1–14.2, 
p = 0.025), with an increased C-index and lower AIC value compared to TILs. Measuring TILs using H&E 
stained sections could stratify the prognosis of stage III colon cancer. Considering host immunity, using 
the combination of TILs and NLR, allowed the prognosis to be stratified in more detail.
Colon cancer management includes curative surgical resection and adjuvant chemotherapy if indicated. In stage III 
colon cancer, adjuvant chemotherapy using the FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) regimen is 
regarded as a standard of care1. In a pooled analysis published recently, which tried to compare the noninferiority of 
3 months and 6 months adjuvant therapy with either FOLFOX or CAPOX (capecitabine and oxaliplatin), the non-
inferiority was not confirmed in the overall stage III colon cancer cohort2. However, in a lower-risk group, which 
was defined as T1, T2, or T3 and N1 cancers, it was shown that 3 months of therapy was as effective as 6 months, 
especially in patients treated with CAPOX. Thus, risk stratification could identify the patients most likely to benefit 
from more or less chemotherapy treatment and enable clinicians to balance expected survival gain against common 
therapeutic toxicities such as oxaliplatin-induced neuropathy in patients with stage III colon cancer3.
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Tumor-infiltrating lymphocytes (TILs) are thought to be an important indicator reflecting the local 
immune-related tumor microenvironment4. An immunoscore has been suggested, which is designed to count 
tumor-infiltrating T-cells using a combination of both CD3+ and CD8+ densities measured in the invasive 
margin and tumor center of colon cancer5. A recent international validation study has demonstrated that TNM 
staging and immunoscore remained significant parameters for survival and immunoscore gave the highest rela-
tive contribution to the risk of all clinical variables, even including TNM stages in patients with stage I–III colon 
cancer6. However, measuring immunoscore is often time and effort consuming due to additional immunohis-
tochemistry (IHC) staining and equipment requirements. This might be a hurdle in achieving the widespread 
clinical use of this score. Previously, TILs have been measured using hematoxylin and eosin (H&E) stained tumor 
sections. Local inflammatory infiltrate was classified as 0–3 using H&E stained tumor sections by the method 
described by Klintrup-Mäkinen (K-M grading)7. It was reported that TILs measured by K-M grading can be used 
as an important prognostic marker in colorectal cancer8–10. Nevertheless, TIL-based stratification when measured 
by the K-M grading system, has not been thoroughly investigated especially for stage III colon cancer patients 
who underwent surgery followed by adjuvant FOLFOX chemotherapy.
The role of cellular-mediated inflammatory response in carcinogenesis, which can be represented as lym-
phocytes, neutrophils, and monocytes in the complete blood cell count, is known to be important11,12. The 
neutrophil-to-lymphocyte ratio (NLR) is a widely used prognostic marker of various tumors including colorec-
tal cancer13–15. The relative convenience and non-invasiveness in obtaining NLR is advantageous. Nevertheless, 
there are still several obstacles on applying NLR in the management of colorectal cancer patients. A very early 
study investigating the impact of NLR in patients with colorectal cancer revealed that NLR might be dependent 
on tumor stage and a prognostic impact was not demonstrated in a multivariable analysis16. The lack of a gen-
erally applicable cut-off value is a main limitation17. Although the explanation for the discordance of the results 
across studies in colorectal cancer is multifactorial, part of the reason may be attributed to the different treatment 
options especially in the administration of chemotherapy regimens13 or simultaneous inclusion of colon and 
rectal cancer patients. The prognostic impact of NLR on rectal cancer measured before surgery might differ from 
that of colon cancer because preoperative chemoradiotherapy for indicated rectal cancer patients could change 
the densities of peripheral inflammatory cells18. For these reasons, the prognostic impact of NLR in stage III colon 
cancer who underwent curative surgery followed by FOLFOX chemotherapy deserves to be investigated, in that 
the impact of NLR might be analyzed on a cohort who underwent relatively uniform treatments.
Current evidence shows that local immune-related tumor response as well as the host immunity have prog-
nostic value, respectively. As far as we know, few studies considered local and systemic inflammatory response 
of tumor simultaneously to evaluate their prognostic value9,19. Furthermore, whether combination of these two 
separate immune reactions, although affect each patient’s prognosis at the same time, provide useful prognostic 
information in stage III colon cancer is unclear. Thus, the aim of this study was to investigate the prognostic 
impact of TILs and NLR, alone or combined, in patients with stage III colon cancer who underwent surgery 
followed by FOLFOX chemotherapy.
Materials and Methods
Patients. From January 2007 to August 2013, patients who underwent surgery followed by adjuvant FOLFOX 
chemotherapy for stage III colon cancer at Gangnam Severance Hospital, Yonsei University College of Medicine 
were initially selected. Patients were included if a slide was available for pathology review and they had under-
gone a complete blood test within 4 weeks of surgery. Patients who underwent an emergency surgery or palliative 
surgery (n = 11), who underwent surgery after diagnosed or treated for intestinal obstruction (n = 5), who had 
inflammatory bowel disease history (n = 2), and who had preoperative chemotherapy (n = 3) were excluded from 
this study because these factors might influence the systemic or local inflammatory status. Finally, 137 patients 
were included in our study. All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki dec-
laration and its later amendments or comparable ethical standards. This study was approved by the institutional 
review board (IRB) of Gangnam Severance Hospital. Informed consent was waived for this retrospective study 
by the IRB.
Treatments and follow-up. All included patients underwent standard colectomy with regional lymphad-
enectomy according to the standard surgical principle20. All tumor staging was evaluated and classified according 
to the definition of the 7th American Joint Committee on Cancer and Union for International Cancer Control 
TNM classification system21. Microsatellite instability (MSI) and KRAS status were evaluated according to the 
techniques described in detail previously22,23. However, not all of the patients underwent these two molecular 
examinations completely. All patients who underwent surgery visited our hospital every 3 months for 3 years 
and then every 6 months until 5 years. At each follow-up visit, serum carcinoembryonic antigen (CEA) level 
was measured. Abdominopelvic computed tomography (CT) scans were performed with an average interval of 
6 months. Chest CT was done at either 6 or 12-month schedules depending on the discretion of the physician. 
18-Fludeoxyglucose (FDG) positron emission tomography (PET) scan was performed on suspicion of recurrence 
as indicated by the surgeon. Colonoscopy was performed usually 1, 3, and 5 years after surgery. Patient follow-up 
lasted until the cut-off date (Dec 2017) or the death of the patient. The median follow-up period was 67.8 months 
(range, 7.5–129.6 months).
Measurement of TILs and NLR. The patients’ slides were reviewed by an experienced pathologist, who had 
no information on the clinical outcomes of the patients. TILs were evaluated using slides of H&E stained sections 
and were scored according to the K-M grading7. As described in detail in other studies8,24, the deepest area of the 
invasive margin of the tumor area was assessed by using a 4-degree scale. A score of 0 was given when there was 
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no increase in lymphocytes, 1 denoted a mild and patchy increase in lymphocytes, 2 denoted a moderate and 
band like lymphocytic infiltrate with some destruction of cancer cell islands, and 3 denoted a marked and florid 
cuplike lymphocytic infiltrate with frequent destruction of cancer cell islands. Macrophages and granulocytes 
could be identified under microscope with H&E staining and excluded in TILs measurements. Area of acute 
inflammation and necrosis was also excluded in measuring TILs. Subsequently, we designated scores 0 and 1 as 
the low TIL group and scores 2 and 3 as the high TIL group in further analysis.
NLR was measured as the ratio of neutrophils divided by lymphocytes. All included patients underwent a 
baseline blood test within 30 days of definite surgery. The median number of days from the measurement of NLR 
to surgery was 6 days (range 1–30 days). The NLR was dichotomized as NLR < 3 (low NLR) and NLR ≥ 3 (high 
NLR). The cut-off value 3 was derived from previous studies measuring its clinical impact25,26.
Statistical analysis. All statistical analyses were performed using the SPSS software, version 23.0 (IBM 
SPSS, Chicago, IL, USA) and R package version 3.4.4 (R-project, Institute for Statistics and Mathematics). 
Differences between groups were analyzed using the chi-square test or Fisher’s exact test for dichotomous 
parameters. Continuous variables were presented as the mean ± standard deviation and were analyzed using the 
Student’s t test. Overall survival (OS) was determined using the data from the date of surgery until death or last 
follow-up. Survival curves were constructed using the Kaplan-Meier method and the log-rank test was used to 
compare survival rates between the groups. In analyses where OS was the outcome, we cross classified TILs and 
NLR of 3 or greater into four categories (high TILs with low NLR, high TILs with high NLR, low TILs with high 
NLR, or low TILs with low NLR) and calculated the Kaplan-Meier curves. According to the survival outcomes, 
the groups were dichotomized as high TILs with low NLR and others, and we used this classification in further 
statistical analysis.
All variables P < 0.1 on univariate analysis were initially entered into the multivariate analysis. Using 
multivariable-adjusted Cox proportional hazards regression analysis done by a backward stepwise selection of 
variables, we evaluated differences in OS by category of TILs and other biomarkers. Models were adjusted for 
operation time, complications, lymph node ratio (LNR), and stage. Next, we examined NLR and TILs in combi-
nation as independent predictors of survival in multivariable-adjusted Cox proportional hazards models. Harrell’s 
concordance index (C-index) and Akaike information criterion (AIC) were calculated for the comparison of 
different predictive models. A higher C-index value would indicate better concordance of survival times and a 
smaller AIC value indicated a more goodness-of-fit for predicting outcomes27,28. P < 0.05 was considered to be 
statistically significant.
Results
Of 137 stage III colon cancer patients who underwent surgery followed by adjuvant FOLFOX chemotherapy, 13 
(9.5%), 49 (35.8%), 44 (32.1%), and 31 (22.6%) patients were classified as K-M grade 0, 1, 2, and 3, respectively. 
Thus, 75 patients (54.7%) were grouped as high TILs and 62 patients (45.2%) were grouped as low TILs. With 
regard to NLR, 97 patients (70.8%) and 40 patients (29.1%) showed low NLR (NLR < 3) and high NLR (NLR ≥ 3), 
respectively. There was greater female predominance in the high TIL group than in the low TIL group (48% in 
high TILs vs. 25.8% in low TILs, P = 0.008). Tumors larger than 5 cm were significantly more common in the high 
NLR group than in the low NLR group (P = 0.017). Among patients with high TILs, 51 patients (68%) showed low 
NLR whereas, 24 patients showed high NLR (P = 0.456) (Table 1, Supplementary data).
In univariate analysis, there was a significant difference in 5-year OS between the high TILs and the low TILs 
(Hazard Ratio, HR: 2.6; confidence interval, CI: 1.1–6.2; P = 0.021). In contrast, there was no survival differ-
ence between the low NLR group and the high NLR group (HR: 1.4, CI: 0.6–3.3, P = 0.331). In addition, LNR 
(P = 0.025), and stage (P = 0.018) were significantly associated with OS. Operation time, complications showed 
trends for association with OS, but these did not reach statistical significance (Table 2).
When we classified patients using the combination of TILs and NLR, there was a significant difference in the 
5-year OS between the groups (5-year OS: 93.8% in high TILs with low NLR, 83.3% in high TILs with high NLR, 
78.3% in low TILs with low NLR and 75% in low TILs with high NLR, P = 0.04) (Fig. 1A). Thus, we dichotomized 
patients into two groups: the high TILs with low NLR group versus others. There was also a significant differ-
ence in 5-year OS between the newly defined classifications (high TILs with low NLR: 93.8% vs. others: 79.1%, 
P = 0.005) (Fig. 1B).
Factors with a p-value less than 0.1 in univariate analysis such as operation time, complications, LNR, 
stage, and TILs were entered into a multivariable analysis in the first stage. Operation time (HR: 2.4, CI: 1–5.6, 
P = 0.043), stage (IIIC vs. IIIB, HR: 0.3, CI: 0.1–0.7, P = 0.009), and TILs (HR: 2.5, CI: 1–5.9, P = 0.032) were 
proved to be independent risk factors for OS (Model 1). In the second stage, we entered high TILs with low NLR 
versus others, instead of TILs, into a multivariable model (Model 2). The results showed that stage (IIIC vs. IIIB, 
HR: 0.3, CI: 0.1–0.7, P = 0.007), and high TILs with low NLR (HR: 4.1, CI: 1.1–4.2, P = 0.025) were independently 
associated with OS. Model 2 showed higher fitness in terms of Akaike information criterion (AIC) (226.289 in 
Model 2 vs. 229.221 in Model 1) and higher predictive power in terms of C-index [0.737, 95% CI (0.623–0.850) in 
Model 2 vs. 0.717, 95% CI (0.604–0.831) in Model 1] than Model 1 (Table 3).
In subgroup analysis according to each stage, 11, 88, and 38 patients were classified into stage IIIA, IIIB, and 
IIIC, respectively. Patients with high TILs with low NLR showed better 5-year OS in the stage IIIB group (100% 
in high TILs with low NLR group vs. 86% in others, P = 0.011). In contrast, there was no difference between the 
two groups in stage IIIA (P = 0.617) and stage IIIC (P = 0.16), respectively (Fig. 2).
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Discussion
This study has demonstrated that TILs measured by H&E staining could stratify the prognosis of patients with 
stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy. Although NLR per se could 
not predict prognosis in our cohort, a combination of TILs and NLR could allow us to distinguish the survival 
outcomes of patients in more detail. Thus, considering local tumor response and systemic immunity by TILs 
measured by H&E staining and NLR might be an affordable and effective option for risk stratification in patient 
with stage III colon cancer.
Variable
High TILs 
(n = 75)
(%)
Low TILs 
(n = 62)
(%) P value
Low NLR
(<3) (n = 97)
(%)
High NLR
(≥3) (n = 40)
(%) P value
Gender
Male 39 (52) 46 (74.2) 0.008 60 (61.9) 25 (62.5) 1.0
Female 36 (48) 16 (25.8) 37 (38.1) 15 (37.5)
Age (years)
<70 61 (81.3) 52 (83.9) 0.822 80 (82.5) 33 (82.5) 1.0
≥70 14 (18.7) 10 (16.1) 17 (17.5) 7 (17.5)
BMI (kg/m2)
<25 58 (77.3) 43 (69.4) 0.332 69 (71.1) 32 (80) 0.299
≥25 17 (22.7) 19 (30.6) 28 (28.9) 8 (20)
ASA grade
I 30 (40) 35 (56.5) 0.160 48 (49.5) 17 (42.5) 0.743*
II 36 (48) 21 (33.9) 39 (40.2) 18 (45)
III 9 (12) 6 (9.7) 10 (10.3) 5 (12.5)
CEA (ng/mL)
<5 56 (74.7) 37 (59.7) 0.069 67 (69.1) 26 (65) 0.689
≥5 19 (25.3) 25 (40.3) 30 (30.9) 14 (35)
Tumor location†
Proximal 25 (33.3) 17 (27.4) 0.465 26 (26.8) 16 (40) 0.155
Distal 50 (66.7) 45 (72.6) 71 (73.2) 24 (60)
Operation time (min)
<300 61 (81.3) 49 (79) 0.830 78 (80.4) 32 (80) 1.0
≥300 14 (18.7) 13 (21) 19 (19.6) 8 (20)
Complications
No 66 (88) 48 (77.4) 0.113 79 (81.4) 35 (87.5) 0.460
Yes 9 (12) 14 (22.6) 18 (18.6) 5 (12.5)
Tumor size (cm)
<5 49 (65.3) 41 (66.1) 1.0 70 (72.2) 20 (50) 0.017
≥5 26 (34.7) 21 (33.9) 27 (27.8) 20 (50)
LVI
Negative 48 (64) 33 (53.2) 0.225 55 (56.7) 26 (65) 0.446
Positive 27 (36) 29 (46.8) 42 (43.3) 14 (35)
No. of metastatic LNs Mean ± SD 4.2 ± 4.8 3.9 ± 3.1 0.703 4 ± 4.3 4.2 ± 3.7 0.758
No. of retrieved LNs Mean ± SD 27.2 ± 14.6 26.7 ± 13.4 0.835 24.8 ± 12.7 32.4 ± 15.7 0.003
LN numbers
<12 3 (4) 4 (6.5) 0.701* 7 (7.2) 0 0.106*
≥12 72 (96) 58 (93.5) 90 (92.8) 40 (100)
LNR
<0.103 39 (52) 29 (46.8) 0.608 47 (48.5) 21 (52.5) 0.710
≥0.103 36 (48) 33 (53.2) 50 (51.5) 19 (47.5)
Stage
IIIA 9 (12) 2 (3.2) 0.134* 10 (10.3) 1 (2.5) 0.331*
IIIB 48 (64) 40 (64.5) 60 (61.9) 28 (70)
IIIC 18 (24) 20 (32.3) 27 (27.8) 11 (27.5)
MSI
MSS 36 (48) 34 (54.8) 0.237 52 (53.6) 18 (45) 0.439*
MSI-High 4 (5.3) 1 (1.6) 2 (2.1) 3 (7.5)
MSI-Low 6 (8) 1 (1.6) 5 (5.2) 2 (5)
No data 29 (38.7) 26 (41.9) 38 (39.2) 17 (42.5)
KRAS
Wild type 19 (25.3) 16 (25.8) 0.299 24 (24.7) 11 (27.5) 0.402
Mutation 16 (21.3) 7 (11.3) 19 (19.6) 4 (10)
No data 40 (53.3) 39 (62.9) 54 (55.7) 25 (62.5)
High TILs N/A N/A 51 (52.6) 24 (60) 0.456
Low TILs N/A N/A 46 (47.4) 16 (40)
NLR < 3 51 (68) 46 (74.2) 0.456 N/A N/A
NLR ≥ 3 24 (32) 16 (25.8) N/A N/A
Table 1. Comparison of patient characteristics and pathologic outcomes according to the TILs and NLR 
respectively. *Fisher’s exact test. †Tumor location: Proximal: Cecum – Transverse colon; Distal: Descending 
colon – Rectosigmoid junction, Two patients with synchronous colon cancer were classified into distal group 
for statistical reason. Abbreviations; TILs: Tumor infiltrating lymphocytes; NLR: Neutrophil to lymphocytes 
ratio; BMI: body mass index; ASA: American society of anesthesiologists; CEA: Carcinoembryonic Antigen; 
LVI: Lymphovascular invasion; LN: Lymph node; LNR: Lymph node ratio; MSS: Microsatellite stability, MSI: 
Microsatellite instability. SD: Standard Deviation.
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The clinical impact of IHC-based measurements of TILs such as CD3, CD8, CD45, and FOXP3 have been 
widely investigated in colorectal cancer29–34. According to a recent international validation study, immunoscore, 
measuring total tumor-infiltrating and cytotoxic tumor-infiltrating T-cells, can stratify patients’ outcomes more 
definitely than TNM stage6. However, one concern of this approach is that a considerable number of patients 
(858/3539, 24%) in the retrospective study were filtered by quality control and could not be included in their 
multinational study6. Among them, 41.6% (357/858) of the excluded patients were associated with the failure 
of obtaining proper IHC results. The IHC-based measurement may not be always successful in some environ-
ments with scarce resources, which prevents the widespread adoption of IHC. Many studies have evaluated the 
impact of TILs measured by the H&E staining of sections from colorectal cancer patients. Huh et al. analyzed 546 
colorectal cancer patients and concluded that TILs have a prognostic impact8. Interestingly, the impact of TILs 
was demonstrated only in stage III colorectal cancer, and not in stage I and II colorectal cancer patients. In that 
study, however, various chemotherapy agents were used, and FOLFOX chemotherapy, which is regarded as the 
standard chemotherapy for stage III colon cancer in current practice, was used for only 6 patients (1%). Another 
study measured the TILs of colorectal cancer patients according to the recommendation of the International 
TILs Working Group in breast cancer10. The patients were composed of stage II and stage III colon and rectal 
cancer patients with or without adjuvant chemotherapy10. In their study, the density of TILs, where high TIL 
level was defined as more than 42%, was independently associated with OS in multivariate analysis. Although 
TILs were proven to be a significant predictor of survival, the results were derived from a heterogeneous cohort, 
Univariate analysis
Hazard Ratio P value
Gender
Male 1
Female 1.6 (0.6–3.8) 0.287
Age (years)
<70 1
≥70 1.2 (0.4–3.2) 0.701
BMI (kg/m2)
<25 1
≥25 0.7 (0.2–1.8) 0.477
ASA grade
1 1 0.460
2 1.6 (0.7–3.6) 0.258
3 0.8 (0.1–4) 0.881
CEA (ng/mL)
<5 1
≥5 0.9 (0.3–2.1) 0.847
Tumor location
Proximal 1
Distal 0.9 (0.4–2.2) 0.960
Operation time (min)
<300 1
≥300 2.1 (0.9–4.9) 0.08
Complications
No 1
Yes 2.2 (0.9–5.2) 0.076
Tumor size (cm)
<5 1
≥5 1.5 (0.7–3.4) 0.27
LVI
Negative 1
Positive 1.4 (0.6–3.1) 0.368
LN numbers
<12 1
≥12 0.6 (0.1–2.9) 0.609
LNR
<0.103 1
≥0.103 2.7 (1.1–6.5) 0.025
Stage
IIIC 1 0.018
IIIB 0.3 (0.1–0.7) 0.007
IIIA 0.2 (0–1.8) 0.165
TILs
High 1
Low 2.6 (1.1–6.2) 0.021
NLR
Low (<3) 1
High (≥3) 1.4 (0.6–3.3) 0.331
TILs and NLR
High TILs with low NLR 1
Others 4.8 (1.4–16.1) 0.011
Table 2. Univariate analysis for overall survival. Abbreviations; BMI: body mass index; ASA: American society 
of anesthesiologists; CEA: Carcinoembryonic Antigen; LVI: Lymphovascular invasion; LN: Lymph node; 
LNR: Lymph node ratio; TILs: Tumor infiltrating lymphocytes; NLR: Neutrophil to lymphocytes ratio. Tumor 
location; Proximal: Cecum – Transverse colon; Distal: Descending colon – Rectosigmoid junction, Two patients 
with synchronous colon cancer were classified into distal group for statistical reason.
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which included stage II and III rectal cancer patients who did not receive radiation therapy. In addition, TILs 
measured by H&E staining in colorectal cancer have been thoroughly investigated by the one group and these 
studies demonstrated that local tumor infiltrate was associated with survival24,35,36. Nevertheless, one concern 
might be that their studies showed a relatively low incidence of 12 or more lymph nodes examined24,35,36. Thus, it 
was difficult to completely exclude the possibility that surgical quality affected the survival outcomes. Therefore, 
these previous studies cannot definitively inform us that the TILs defined by H&E stain may have an impact on 
the prognosis of patients with stage III colon cancer who underwent FOLFOX chemotherapy. Our study demon-
strated that TILs can be used as an independent prognostic factor for patients with stage III colon cancer. The 
strength of the present study is that our group included relatively homogeneously treated patients with a high 
proportion of adequately retrieved lymph nodes (95%) and all patients had undergone adjuvant FOLFOX chemo-
therapy. Our result can be applied relatively easily in clinical practice because an H&E examination is a routine 
procedure for the evaluation of tumor staging.
The clinical impact of NLR per se was not demonstrated in our study. Although many studies concluded that 
NLR is an important inflammatory biomarker in colorectal cancer, there are several issues to be mentioned. 
As depicted in one of the earlier studies, which investigated the impact of NLR in colorectal cancer, Walsh and 
colleagues showed that an NLR greater than 5 correlated with OS only in univariate analysis16. Because NLR was 
dependent on Dukes stage, the significance was lost in multivariate analysis16. According to a study by Li and 
colleagues, which included 5,336 patients and is one of the largest scale studies dealing with this issue for colorec-
tal cancer, NLR dichotomized as 2.72 can predict patients’ OS37. However, in that study, the clinical impact of 
inflammatory markers including NLR was not evident in patients who did not undergo adjuvant chemotherapy. 
The authors explained that the significance of NLR might not be demonstrated due to the overall good survival 
outcome of this subgroup. Malietzis and colleagues analyzed the impact of NLR in 506 colorectal cancer patients 
who did not undergo adjuvant chemotherapy25. They showed that an NLR of more than 3 was identified as an 
independent prognostic factor for disease-free survival. Interestingly, this correlation did not last when OS was 
evaluated. Although we could not elucidate the reason of the negative impact of NLR per se in our group, it is 
worth mentioning that most of the previous studies evaluating the impact of NLR in colorectal cancer include 
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Figure 1. Overall survival according to the combination of TILS and NLR. (A) 4 groups comparison (B) 2 
group comparison.
Model1 Model 2
Hazard Ratio (CI) P value Hazard Ratio (CI) P value
Operation time (min) <300 vs. ≥300 2.4 (1–5.6) 0.043
Complications No vs. Yes 2.2 (0.9–5.4) 0.075
LNR <0.103 vs. ≥0.103
Stage
IIIC 1 0.026 1 0.023
IIIB 0.3 (0.1–0.7) 0.009 0.3 (0.1–0.7) 0.007
IIIA 0.2 (0–2.3) 0.243 0.3 (0–2.8) 0.325
TILs High vs. Low 2.5 (1–5.9) 0.032
TILs and NLR High TILs and low NLR vs. others 4.1 (1.1–14.2) 0.025
C-index (95% Confidence Interval) 0.717(0.604–0.831) 0.737(0.623–0.850)
AIC 229.221 226.289
Table 3. Multivariate analysis using different parameters. Abbreviations; LNR: Lymph node ratio; TILs: 
Tumor infiltrating lymphocytes; NLR: Neutrophil to lymphocytes ratio. C-index: Harrell’s concordance index; 
AIC: Akaike information criterion. Factors with p value less than 0.1 in univariate analysis were entered into 
multivariate analysis.
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heterogeneous groups of patients. Most of the studies included colon cancer and rectal cancer patients simultane-
ously and patients who either underwent adjuvant chemotherapy or did not. In addition, the chemotherapeutic 
agents and regimens were diverse and included 5FU, capecitabine, FOLFOX, etc. As we already know, rectal can-
cer patients usually underwent preoperative or postoperative radiation therapies, thus the radiation effect cannot 
be ignored in the statistical analysis. In node-positive colon cancer patients, the benefit of adjuvant chemotherapy 
is well established. Thus, the real effects of NLR might be more fairly evaluated in environments where chemo-
therapy was considered as a treatment option. Nevertheless, considering our relatively small number of patients, 
whether NLR has an impact on patients with stage III colon cancer remains undetermined.
Pine et al. analyzed the correlation of TILs and NLR and its impact on survival using 358 colorectal cancer 
patients19. In their study, TILs (expressed as a lymphocytic reaction at the invasive margin in their paper) were 
correlated with the NLR, which was divided using a cut-off value of 5. There was a significantly lower rate of 
patients with more than 5 NLR in the high TIL group (15.3% in the high TIL group vs. 29.2% in the low TIL 
group, P = 0.005). NLR dichotomized as 5 was proven to be an independent prognostic factor for OS, how-
ever, TILs were not an independent factor in multivariate analysis. The authors did not include the combination 
of these two parameters in statistical analysis. Contrary to their study, our study showed no direct correlation 
between TILs and NLR, however, TILs have an impact on OS and NLR did not. Again, we want to point out there 
were some differences in the inclusion criteria and OS outcomes might differ between the two studies because of 
the difference of included study periods.
One of the interesting findings in our study is that the combination of TILs with NLR had a higher relative 
contribution to the risk stratification of patients’ survival than TILs alone. Patients with high TILs showed differ-
ent prognosis according to the NLR group (5-year OS; high TILs with low NLR, 93.8%, vs. high TILs with high 
NLR, 83.3%, P = 0.038). In contrast, this kind of discrimination was not demonstrated in patients in the low TIL 
group (5-year OS; low TILs with low NLR, 78.3%, vs. low TILs with high NLR, 75%, P = 0.892). Although the 
underlying reason for this association is not evident, it has been speculated that the NLR might have a partial 
effect on patient survival. One step further, our study showed that even among the same sub-staging, risk stratifi-
cation may be possible according to the combination of local tumor immune response and host immunity defined 
as TILs and NLR. In patients with stage IIIB, the OS was significantly better in patients with high TILs with low 
NLR than in others (P = 0.011), although this correlation was not demonstrated in patients with stage IIIA or 
IIIC. Considering the distinct difference between groups of 5-year OS in stage IIIC (83.3% vs. 61.5%, P = 0.16) 
and the low number of included patients with stage IIIA (n = 11), these results might be derived from a type II 
error, which might be a limitation of this retrospective study. Further study is warranted to validate our findings.
This study has several limitations, which deserve to be mentioned. The small number of patients included in 
this retrospective study might be a main limitation. The TIL measurement was performed by one single pathol-
ogist, which might be a source of bias. However, previous studies evaluating inter-observer agreement on this 
subject showed good agreement (kappa value: 0.81 in each study)24,35. The cut-off value to discriminate between 
the high or low group using NLR is not strongly established. According to a recent review13, the cut-off value 
ranged from 2 to 5 and the proportion of the high NLR group might be different between the studies or may 
be diverse between races. This might be a critical limitation in the general application of this value17. Although 
our group used 3 as a reference value for dichotomization, if we applied the cut-off value as 5 or 2.72 (which 
was recommended by Li and colleagues37), there was no difference of OS between the two subgroups divided by 
NLR, respectively. There are several reports on the clinical impact of MSI, KRAS, NRAS, and BRAF mutations 
in the prognosis of colorectal cancer38–40. The effect of these genomic alterations in colorectal cancer may enter 
into the multivariable analysis; however, due to the retrospective study design, it was not possible to include all 
these variables in the analysis. Finally, the H&E-based K-M grading of inflammatory infiltrate has some inherent 
limitations compared to the IHC-based measurements. As explained in several previous studies6,36, the K-M 
grade provides a measure of the overall, generalized inflammatory cell infiltrate, in contrast, immunoscore meas-
ured the host adaptive T-lymphocyte. Consequently, the K-M grade can be elevated by not only the increas-
ing tumor-infiltrating T lymphocytes, but also by increasing the density of the innate immune infiltrate such 
as neutrophils and macrophages6,36. Improvement of prognostic power by the combination of TILs and NLR 
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Figure 2. Overall survival according to the combination of TILs and NLR in each stage. (A) Stage IIIA (n = 11), 
(B) Stage IIIB (n = 88), (C) Stage IIIC (n = 38).
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in our study might suggest one possibility to overcome this limitation of K-M based tumor infiltrate measure-
ments, although these results should be validated in other cohorts. In fact, Turner and colleagues have already 
demonstrated that the combination of two markers, such as intratumoral immune infiltrate and NLR, could 
further stratify the prognosis independent of standard high-risk criteria. Patients with prominent systemic and 
local inflammatory response (low chronic inflammatory cell density with high NLR) showed the worst outcome 
(5-year OS 55.8%) in stage II colon cancer9.
In conclusion, our study demonstrated that TILs measured by H&E staining and a combination of TILs and 
NLR could stratify patients’ survival in stage III colon cancers. These parameters can be obtained during clinical 
practice without any additional effort or equipment. Thus, we believe this approach is worth considering in view 
of cost-effectiveness and convenience. Evaluation of chemotherapy efficacy according to risk stratification using 
these easily obtained biomarkers may be required to select patients who may benefit from reduced chemotherapy 
in stage III colon cancer.
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